These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25382700)

  • 21. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
    Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
    J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD; Cheung CM; Rybak MJ
    J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
    Barriere SL
    Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.
    Das B; Sarkar C; Das D; Gupta A; Kalra A; Sahni S
    Ther Adv Infect Dis; 2017 Mar; 4(2):49-73. PubMed ID: 28634536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
    Mendes RE; Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):113-7. PubMed ID: 22078909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
    Liapikou A; Dimakou K; Toumbis M
    Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
    Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
    Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method.
    Mendes RE; Farrell DJ; Sader HS; Streit JM; Jones RN
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):275-9. PubMed ID: 25618421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
    Yin LY; Calhoun JH; Thomas TS; Wirtz ED
    J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.
    Chan C; Hardin TC; Smart JI
    Future Microbiol; 2015; 10(8):1325-38. PubMed ID: 26083676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new lipoglycopeptide: telavancin.
    Nannini EC; Stryjewski ME
    Expert Opin Pharmacother; 2008 Aug; 9(12):2197-207. PubMed ID: 18671473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.
    Nawar T; Kanafani ZA
    Expert Rev Anti Infect Ther; 2015 Jul; 13(7):825-33. PubMed ID: 26059192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
    Putnam SD; Sader HS; Moet GJ; Mendes RE; Jones RN
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
    Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
    Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.